Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 15/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002670 | 0.94 | ADORA2B (0.49) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL9885749 | 0.92 | ADORA2B (0.45) | ADORA2BADORA2AADORA3ADORA1CHRM4 | |
| SCHEMBL16299181 | 0.91 | ADORA2B (0.46) | ADORA2BADORA2AADORA3ADORA1CHRM4 | |
| SCHEMBL1242614 | 0.91 | ADORA2B (0.46) | ADORA2BADORA2AADORA3ADORA1CHRM4 | |
| SCHEMBL1002030 | 0.91 | ADORA2B (0.45) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1243837 | 0.91 | ADORA2B (0.47) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1243464 | 0.90 | ADORA2B (0.49) | ADORA2BADORA2AADORA3ADORA1CHRM4 | |
| SCHEMBL1243251 | 0.90 | ADORA2B (0.44) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1243808 | 0.89 | ADORA2A (0.44) | ADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL1243077 | 0.88 | ADORA2B (0.43) | ADORA2BADORA2AADORA3ADORA1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221821-B2 | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds | Forest Laboratories Holdings, Limited (BM) | 2015-12-29 | — | — | US | disclosed |
| US-9221821-B2 | Methods for the synthesis of 1,3-substituted aminouracils and other xanthine-related compounds | Forest Laboratories Holdings, Limited (BM) | 2015-12-29 | — | — | US | disclosed |
| EP-2029143-B1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-8258142-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258142-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258142-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | DOGWOOD PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8193200-B2 | administering a substituted 8-(3-pyridyl)-xanthine; ulcerative colitis; Crohn's disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193200-B2 | administering a substituted 8-(3-pyridyl)-xanthine; ulcerative colitis; Crohn's disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193200-B2 | administering a substituted 8-(3-pyridyl)-xanthine; ulcerative colitis; Crohn's disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110082139-A1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | ALLERGAN SALES, LLC | 2011-04-07 | — | — | US | disclosed |
| US-20110082139-A1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | ALLERGAN SALES, LLC | 2011-04-07 | — | — | US | disclosed |
| US-7884100-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | PGXHEALTH, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884100-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | PGXHEALTH, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884100-B2 | Substituted 8-[6-amino-3-pyridyl]xanthines | PGXHEALTH, LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | EMORY UNIVERSITY | 2008-07-24 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ALLERGAN SALES, LLC | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082139-A1 | SUBSTITUTED 8-[6-AMINO-3-PYRIDYL]XANTHINES | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 3/4885 |
| US-20080004292-A1 | Substituted 8-[6-amino-3-pyridyl]xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 3/4885 |
| US-20080176845-A1 | Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA2A 2/4885ADORA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.